Moreover, the effectiveness and safety of afatinib was determined by Yang JC and colleagues in a combined post hoc analysis of a single group phase 2 (LUX-Lung 2) trial and a randomized phase 3 (LUX-Lung 3 and LUX-Lung 6) clinical trial with EGFR mutation-positive advanced (stage IIIb–IV) lung adenocarcinomas patients, reporting fascinating results. Here, EGFR is linked to lung adenocarcinoma.